Drosou Anna, Kirsner Robert S, Welsh Esperanza, Sullivan Tory P, Kerdel Francisco A
Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, Miami, Florida, USA.
J Cutan Med Surg. 2003 Sep-Oct;7(5):382-6. doi: 10.1007/s10227-002-0134-1. Epub 2003 Sep 24.
Infliximab is a monoclonal antibody against tumor necrosis factor alpha currently approved by the U.S. FDA for the treatment of Crohn's disease and rheumatoid arthritis. Recently, a controlled trial reported its effectiveness for psoriasis.
The object of our study was to evaluate the efficacy and safety of infliximab for inflammatory or autoimmune cutaneous disorders.
A retrospective chart review was performed for patients who received infliximab at the University of Miami, Cedars Medical Center.
Patients with various disease, including panniculitis, pityriasis rubra pilaris, eosinophilic fasciitis, discoid lupus erythematosus, and necrobiosis lipoidica diabeticorum, received infliximab infusion at a dose of 5 mg/kg. All patients had refractory disease or adverse effects to previous therapy, which included cyclosporine, systemic steroids, azathioprin, clofazimine, mycophenolate mofetil, acitretin, UVB, and thalidomide. Six out of the seven patients improved after treatment.
Infliximab was well tolerated in most patients and the majority benefited from the use of infliximab.
英夫利昔单抗是一种抗肿瘤坏死因子α的单克隆抗体，目前已获美国食品药品监督管理局批准用于治疗克罗恩病和类风湿性关节炎。最近，一项对照试验报告了其对银屑病的有效性。
我们研究的目的是评估英夫利昔单抗治疗炎性或自身免疫性皮肤疾病的疗效和安全性。
对在迈阿密大学雪松医疗中心接受英夫利昔单抗治疗的患者进行回顾性病历审查。
患有各种疾病的患者，包括脂膜炎、毛发红糠疹、嗜酸性筋膜炎、盘状红斑狼疮和糖尿病性类脂质渐进性坏死，接受了剂量为5mg/kg的英夫利昔单抗输注。所有患者对先前的治疗（包括环孢素、全身性类固醇、硫唑嘌呤、氯法齐明、霉酚酸酯、阿维A、紫外线B和沙利度胺）均有难治性疾病或不良反应。7名患者中有6名在治疗后病情改善。
大多数患者对英夫利昔单抗耐受性良好，大多数患者从使用英夫利昔单抗中获益。
